NCT05766371: Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer
- State
- Under way
- Phase
- Phase 2
- People
- 48 planned
- Started
- 15 Dec 2023
- Primary completion
- 31 May 2027
- Arms
- Pembrolizumab, 177Lu-PSMA-617
- Results
- None posted
- 13 Mar 2023: Trial registered
- 15 Dec 2023: Trial started